Table 4. Sensitivity analysis of the proposed Bayesian phase I/II drug-combination design under different prior specifications.

	Selection percentage						Number of treated patients
Sc.	α,β ~ Ga(0.1, 0.1)			α,β ~ Ga(0.05,0.05)			α,β ~ Ga(0.1, 0.1)			α,β ~ Ga(0.05,0.05)
1	2.0	21.0	25.4	2.0	19.9	27.1	7.8	15.7	20.2	7.7	15.7	20.8
	0.1	8.2	41.8	0	9.0	40.2	7.4	9.6	18.3	7.1	9.6	18.1
2	5.4	46.5	2.9	4.9	45.9	3.7	10.6	21.6	9.6	10.5	21.4	9.4
	0.4	21.0	20.3	0.2	22.9	17.9	8.8	14.4	13.0	8.8	14.9	12.5
3	2.0	6.3	69.6	0.9	6.1	70.2	7.2	10.1	36.3	6.8	9.8	36.4
	0.1	1.2	19.4	0	1.4	19.9	7.1	6.5	12.1	7.0	6.6	12.5
4	16.9	24.7	0.2	15.6	24.6	0.3	15.2	16.4	4.0	15.1	16.0	4.3
	4.8	44.2	2.8	4.1	45.1	3.0	13.1	20.6	6.8	13.2	20.4	6.2